Jefferies analyst Faisal Khurshid initiated coverage of Design Therapeutics with a Buy rating and $15 price target. The firm believes the company's DT-216P2 readout in the second half of 2026 can deliver a meaningful frataxin signal in Friedreich ataxia. The analyst sees upside on the news, saying the readout is "more de-risked than appreciated" given that the Phase 1 already showed proof-of-mechanism, and the new Phase 2 formulation "solves the exposure problem."
